

## Publications 2014 GERCOR

1. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. Diouf M, Chibaudel B, Filleron T, Tournigand C, Hug de Larauze M, Garcia-Larnicol ML, Dumont S, Louvet C, Perez-Staub N, Hadengue A, de Gramont A, Bonnetain F. *Health Qual Life Outcomes*. 2014 May 13;12:69.
2. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. *Eur J Cancer*. 2014 Nov;50(17):2983-93.
3. DATECAN project published in *Ann Oncol*. 2014 Jul 28. Bellera CA et al. "Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)".
4. Prognostic Value of Angiopoietin-2 for death risk stratification in Patients with Metastatic Colorectal Carcinoma. Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouche O, Fratte S, Goncalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C. *Cancer Epidemiol Biomarkers Prev*. 2015 Jan 12. (Prognostic GERCOR model).
5. Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study. Chibaudel B, Lacave R, Lefevre M, Soussan P, Antoine M, Périé S, Belloc JB, Banal A, Albert S, Chabolle F, Céruse P, Baril P, Gatineau M, Housset M, Moukoko R, Benetkiewicz M, de Gramont A, Bonnetain F, Lacau St Guily J. *Cancer Med*. 2015 Feb 14.
6. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. Hebbar M, Chibaudel B, André T, Mineur L, Smith D, Louvet C, Dutel JL, Ychou M, Legoux JL, Mabro M, Faroux R, Auby D, Brusquant D, Khalil A, Truant S, Hadengue A, Dalban C, Gayet B, Paye F, Pruvot FR, Bonnetain F, Taieb J, Brucker P, Landi B, Flesch M, Carola E, Martin P, Vaillant E, de Gramont A; Group Coopérateur Multidisciplinaire en Oncologie (GERCOR) Group. *Ann Oncol*. 2015 Feb;26(2):340-7.

7. Lieu C, Renfro LA, de Gramont A, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD clinical trials program. *J Clin Oncol*. 2014 Sep 20;32(27):2975-2982. DOI: 10.1200/JCO.2013.54.9329.
8. Shi Q, De Gramont A, Grothey A, Zalcborg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams RA, Saltz L, Goldberg RM, Punt CJA, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Diaz-Rubio E, Porschen R, Tebbutt NC, Fuchs CS, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse ME, Sargent DJ. Individual patient data analysis of progression-free survival versus overall survival as a first-line endpoint for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database. *J Clin Oncol*. Epub 2014 Nov 10. DOI: 10.1200/JCO.2014.56.5887.
9. Guimbaud R., Louvet C., Ries P., Ychou M., Maillard E., André T., Gornet JM., Aparicio T., Nguyen S., Azzedine A., Etienne P-L, Boucher E., Rebischung C., Hammel P., Rougier P., Bedenne L., Bouché O. Prospective randomized multicenter Phase III study of fluorouracil leucovorin and irinotecan vs epirubicin cisplatin and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (FFCD, FNCLCC and GERCOR) Study. *Journal of Clinical Oncology* 10/2014; 32(31). DOI:10.1200/JCO.2013.54.1011.